Evidence mapPaperPMID 35054972Full record

ReviewInternational journal of molecular sciences2022

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.

Gracia Fahed, Laurence Aoun, Morgan Bou Zerdan, Sabine Allam, Maroun Bou Zerdan, Youssef Bouferraa, Hazem I Assi

2 registry-linked trialsAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 754 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
754citing papers in PubMed, 7 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05702437 unknown statusnot on this mapstarted 2023, after this paper: background citation

The Effects of Metabolic Syndrome and Its Components on Cognitive Performance and Physical Activity Level in Middle-age Individuals

Typeobservational_patient_registrySponsorIstanbul University - CerrahpasaRan2023 to 2025Enrolled82ConditionsMetabolic SyndromeArmsassessment of cognitive performance
NCT07704749 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Rural Initiative for Inflammatory Screening & Engagement for Women

TypeinterventionalSponsorTexas Tech University Health Sciences CenterRan2026 to 2027Enrolled125ConditionsCardiometabolic Risk FactorsArmsRISE-W Micro-Movement Program
3 · Its place in the literature

Who cites it

754 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

694 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gracia FahedFaculty of Medicine, American University of Beirut, Beirut 2020, Lebanon.
Laurence AounFaculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh 1200, Lebanon.
Morgan Bou ZerdanFaculty of Medicine, American University of Beirut, Beirut 2020, Lebanon.
Sabine AllamFaculty of Medicine, University of Balamand, Beirut 1100, Lebanon.
Maroun Bou ZerdanDepartment of Internal Medicine, SUNY Upstate Medical University, New York, NY 13205, USA.ORCID 0000-0002-9229-3079
Youssef BouferraaDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Hazem I AssiDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut 2020, Lebanon.ORCID 0000-0002-8483-0938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis of MetS encompasses multiple genetic and acquired entities that fall under the umbrella of insulin resistance and chronic low-grade inflammation. If left untreated, MetS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases (CVDs). Given that CVDs constitute by far the leading cause of morbidity and mortality worldwide, it has become essential to investigate the role played by MetS in this context to reduce the heavy burden of the disease. As such, and while MetS relatively constitutes a novel clinical entity, the extent of research about the disease has been exponentially growing in the past few decades. However, many aspects of this clinical entity are still not completely understood, and many questions remain unanswered to date. In this review, we provide a historical background and highlight the epidemiology of MetS. We also discuss the current and latest knowledge about the histopathology and pathophysiology of the disease. Finally, we summarize the most recent updates about the management and the prevention of this clinical syndrome.

Indexed as

BiomarkersChronic DiseaseDisease ManagementDisease SusceptibilityHumansInflammationInsulin ResistanceMetabolic SyndromeMitochondriaOrgan SpecificityPrevalencePublic Health SurveillanceBiomarkersinsulin resistancemetabolic syndromenutraceuticals

Identifiers

PMID35054972
PMCPMC8775991

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.